Summary

Although single-agent second-line chemotherapy has limited efficacy in unselected non-small cell lung cancer (NSCLC), its effect in advanced anaplastic Kinase positive (ALK+) NSCLC is uncertain. Crizotinib has marked clinical activity in ALK+ NSCLC [Camidge DR et al. Lancet Oncol 2012; Kim DW et al. ASCO 2012. Abstract 7533]. The PROFILE 1007 [NCT00932893] trial compared the efficacy and safety of crizotinib with standard chemotherapy as second-line therapy in patients with advanced ALK+ NSCLC.